|
1
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
3
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zakowski MF, Ladanyi M and Kris MG:
Memorial sloan-kettering cancer center lung cancer oncogenome
group. EGFR mutations in small-cell lung cancers in patients who
have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yano S, Wang W, Li Q, et al: Hepatocyte
growth factor induces gefitinib resistance of lung adenocarcinoma
with epidermal growth factor receptor-activating mutations. Cancer
Res. 68:9479–9487. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li D, Ambrogio L, Shimamura T, et al:
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in
preclinical lung cancer models. Oncogene. 27:4702–4711. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang W, Li Q, Takeuchi S, et al: Met
kinase inhibitor E7050 reverses three different mechanisms of
hepatocyte growth factor-induced tyrosine kinase inhibitor
resistance in EGFR mutant lung cancer. Clin Cancer Res.
18:1663–1671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakagawa T, Takeuchi S, Yamada T, et al:
Combined therapy with mutant-selective EGFR inhibitor and Met
kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant
lung cancer. Mol Cancer Ther. 11:2149–2157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miller VA, Hirsh V, Cadranel J, et al:
Afatinib versus placebo for patients with advanced, metastatic
non-small-cell lung cancer after failure of erlotinib, gefitinib,
or both and one or two lines of chemotherapy (LUX-Lung 1): a phase
2b/3 randomised trial. Lancet Oncol. 13:528–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Katakami N, Atagi S, Goto K, et al:
LUX-Lung 4: a phase II trial of afatinib in patients with advanced
non-small-cell lung cancer who progressed during prior treatment
with erlotinib, gefitinib, or both. J Clin Oncol. 31:3335–3341.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sequist LV, Pawel J, Garmey EG, et al:
Randomised phase II study of erlotinib plus tivantinib versus
erlotinib plus placebo in previously treated non-small-cell lung
cancer. J Clin Oncol. 29:3307–3315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakamura T, Sueoka-Aragane N, Iwanaga K,
et al: A noninvasive system for monitoring resistance to epidermal
growth factor receptor tyrosine kinase inhibitors with plasma DNA.
J Thorac Oncol. 6:1639–1648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yano S, Yamada T, Takeuchi S, et al:
Hepatocyte growth factor expression in EGFR mutant lung cancer with
intrinsic and acquired resistance to tyrosine kinase inhibitors in
a Japanese cohort. J Thorac Oncol. 6:2011–2017. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu HA, Arcila ME, Rekhtman N, et al:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mizuno S and Nakamura T: HGF-MET cascade,
a key target for inhibiting cancer metastasis: The impact of NK4
discovery on cancer biology and therapeutics. Int J Mol Sci.
14:888–919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang WG, Martin TA, Parr C, et al:
Hepatocyte growth factor, its receptor and their potential value in
cancer therapies. Crit Rev Oncol Hematol. 53:35–69. 2005.
View Article : Google Scholar
|
|
19
|
Martin TA, Parr C, Davies G, et al: Growth
and angiogenesis of human breast cancer in a nude mouse tumor model
is reduced by NK4, a HGF/SF antagonist. Carcinogenesis.
24:1317–1323. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wisles M, Rabbe N, Marchal J, et al:
Hepatocyte growth factor production by neutrophils infiltrating
bronchioloalveolar subtype pulmonary adenocarcinoma: Role in tumor
progression and death. Cancer Res. 63:1405–1412. 2003.
|
|
21
|
Grenier A, Chollet-Martin S, Crestani B,
et al: Presence of a mobilizable intracellular pool of hepatocyte
growth factor in human polymorphonuclear neutrophils. Blood.
99:2997–3004. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goldstrow P, Crowley J, Chansky K, et al:
The IASLC Lung Cancer Staging Project: Proposals for the revision
of the TNM stage groupings in the forthcoming (seventh) edition of
the TNM classification of malignant tumours. J Thorac Oncol.
2:706–714. 2007. View Article : Google Scholar
|
|
23
|
Jackman D, Pao W, Riely GJ, et al:
Clinical definition of acquired resistance to epidermal growth
factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar
|
|
24
|
Takanami I, Tanana F, Hashizume T, et al:
Hepatocyte growth factor and c-Met/hepatocyte growth factor
receptor in pulmonary adenocarcinomas: An evaluation of their
expression as prognostic markers. Oncology. 53:392–397. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegfried JM, Weissfeld LA, Luketich JD,
et al: The clinical significance of hepatocyte growth factor for
non-small cell lung cancer. Ann Thorac Surg. 66:1915–1918. 1998.
View Article : Google Scholar
|
|
26
|
Toiyama Y, Miki C, Inoue Y, et al: Serum
hepatocyte growth factor as a prognostic marker for stage I or II
colorectal cancer patients. Int J Cancer. 125:1657–1662. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka K, Miki C, Wakuda R, et al:
Circulating level of hepatocyte growth factor as a useful tumor
marker in patients with early-stage gastric carcinoma. Scand J
Gastroenterol. 8:754–760. 2004. View Article : Google Scholar
|
|
28
|
Gupta A, Karakiewicz PI, Roehrborn CG, et
al: Predictive value of plasma hepatocyte growth factor/scatter
factor levels in patients with clinically localized prostate
cancer. Clin Cancer Res. 14:7385–7390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Seidel C, Borset M, Turesson I, et al:
Elevated serum concentrations of hepatocyte growth factor in
patients with multiple myeloma. The Nordic Myeloma Study Group.
Blood. 91:1806–1812. 1998.
|
|
30
|
Arcila MA, Oxnard GR, Nafa K, et al:
Rebiopsy of lung cancer patients with acquired resistance to EGFR
inhibitors and enhanced detection of the T790M mutation using a
locked nucleic acid-based assay. Clin Cancer Res. 17:1169–1180.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suda K, Murakami I, Katayama, et al:
Reciprocal and complementary role of MET amplification and EGFR
T790M mutation in acquired resistance to kinase inhibitors in lung
cancer. Clin Cancer Res. 16:5489–5498. 2010. View Article : Google Scholar : PubMed/NCBI
|
